(RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older ...

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

The FreeStyle Libre 3 system is the latest generation in Abbott (ABT)'s FreeStyle Libre portfolio – the most prescribed and affordable integrated continuous glucose monitoring (iCGM) system in the ...

(RTTNews) - Abbott (ABT) said late-breaking clinical data showed the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

Abbott Laboratories Inc. landed U.S. FDA clearance for its Freestyle Libre 3 integrated continuous glucose monitoring system (CGM)’s reader device a bit earlier than expected. With the regulatory ...

The FreeStyle Libre 3 glucose monitoring system (Abbott) has been granted a CE mark for use by people with diabetes in the countries of the European Union (EU). The next-generation FreeStyle Libre 3 ...

Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes ...

ABBOTT PARK, Ill., April 8, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading 3 continuous glucose monitoring (CGM) technology, can ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has cleared a next-generation integrated ...

MARD is considered the simplest measurement of sensor accuracy 2 and represents the difference between a CGM system's glucose readings and a reference blood glucose measurement. The lower the MARD, ...

Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...